Uncategorized

Uncategorized

New Releases from NCBI BookshelfFaricimab (Vabysmo): Indication: For the treatment of macular edema secondary to retinal vein occlusion: Reimbursement Recommendation [Internet].​Faricimab (Vabysmo): Indication: For the treatment of macular edema secondary to retinal vein occlusion: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Vabysmo be reimbursed by public drug plans for the treatment of macular edema secondary […]

Uncategorized

New Releases from NCBI BookshelfTalquetamab (Talvey): Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy: Reimbursement Recommendation [Internet].​Talquetamab (Talvey): Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Talvey not be reimbursed by public drug plans for the treatment of adult patients

Uncategorized

New Releases from NCBI BookshelfIptacopan (Fabhalta): Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia: Reimbursement Recommendation [Internet].​Iptacopan (Fabhalta): Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Fabhalta be reimbursed by public drug plans for the treatment of adult patients with

Uncategorized

New Releases from NCBI BookshelfTarlatamab (Imdelltra): Indication: The treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy: Reimbursement Recommendation [Internet].​Tarlatamab (Imdelltra): Indication: The treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Imdelltra be reimbursed by public drug plans for the treatment of extensive-stage small cell

Scroll to Top